Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alfama Inc.

www.alfama.com.pt

Latest From Alfama Inc.

Deals Shaping the Medical Industry (10/2008)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions Database, providing comprehensive transaction coverage from 1991 to the present.

Alfama and hemoCORM join forces on carbon monoxide research

Two companies active in carbon monoxide research, Alfama and hemoCORM, have merged to create a leader in the field of carbon monoxide-releasing molecules (CORM). Researchers at both companies have been developing compounds that can release carbon monoxide in minute amounts after oral or injectable administration, and have shown promise in a range of acute and chronic inflammatory diseases.

Neurology Immune Disorders

hemoCORM Ltd.

The founders of European start-ups hemoCORM Ltd. and Alfama are hoping to harness potentially therapeutic effects of carbon monoxide (CO) through developing a range of CO releasing molecules that deliver the molecule into the body under certain conditions.
BioPharmaceutical Europe

Alfama

The founders of European start-ups Alfama and hemoCORM Ltd. are hoping to harness potentially therapeutic effects of carbon monoxide (CO) through developing a range of CO releasing molecules that deliver the molecule into the body under certain conditions.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders > Autoimmune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Portugal
  • Parent & Subsidiaries
  • Alfama Inc.
  • Senior Management
  • Nuno Arantes-Oliveira, PhD, Pres. & CEO
    Maurice Matteodo, CFO
  • Contact Info
  • Alfama Inc.
    Phone: (351) 21 424 0001
    Taguspark, núcleo central 267
    Porto Salvo, 2740-122
    Portugal
Advertisement
Advertisement
UsernamePublicRestriction

Register